Literature DB >> 33741764

Dedifferentiation in Breast Metastasis of Endometrial Carcinoma: A Diagnostic Dilemma.

Varsha I Shah, Sian E Morgan, Martin Köbel, Cheng-Han Lee, W Glenn McCluggage.   

Abstract

Most breast tumors are primary to this site; breast metastasis of endometrial origin is extremely rare. Low-grade endometrioid endometrial carcinomas can undergo dedifferentiation to undifferentiated carcinoma but such transformation at a metastatic site has been reported previously in only 2 cases. We report a case of dedifferentiation occurring in an isolated solitary breast metastasis of a low-grade endometrioid endometrial carcinoma. A 64-yr-old woman presented with a breast mass 2 yr after initial diagnosis of a grade 1 FIGO stage IIIA endometrioid endometrial carcinoma. Ultrasound guided biopsy of the breast mass showed a grade 1 endometrioid carcinoma which was diffusely estrogen receptor and PAX8-positive, consistent with metastasis from the previous endometrial carcinoma. The tumor initially responded to Letrozole therapy but then abruptly increased in size. Mastectomy revealed a poorly differentiated malignant tumor with morphology and immunophenotype (including loss of ARID1A and ARID1B immunoreactivity) consistent with undifferentiated endometrial carcinoma with no residual low-grade component. Awareness of the phenomenon of dedifferentiation of endometrial carcinoma in a metastatic site is important to avoid misdiagnosis as a primary breast cancer or metastasis from another primary site.
Copyright © 2021 by the International Society of Gynecological Pathologists.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 33741764     DOI: 10.1097/PGP.0000000000000770

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  1 in total

1.  Vulvar neuroendocrine carcinoma that is independent of merkel cell polyomavirus and human papillomavirus suggests endometrial cancer recurrence: a case report.

Authors:  Tomoko Hirakawa; Mitsutake Yano; Haruto Nishida; Shimpei Sato; Kaei Nasu
Journal:  BMC Endocr Disord       Date:  2022-03-29       Impact factor: 2.763

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.